Catalog No.
Product Name
Application
Product Information
Citations
-
ADC cytotoxin
NMT-IN-7 is a potent inhibitor of N-myristoyl transferase (NMT), exhibiting IC50 values of 2.1 nM for HsNMT1M and 0.6 nM for SU-DHL-10 cells. This compound functions effectively as an antibody-drug conjugate (ADC) cytotoxin, demonstrating significant potential in targeted cancer therapy. Its selective inhibition of NMT may facilitate the study of myristoylation in biological processes and contribute to the development of novel therapeutic strategies. -
ADC Cytotoxin
Fmoc-MMAE is a protective group-conjugated derivative of monomethyl auristatin E (MMAE), functioning primarily as a tubulin inhibitor. This compound exhibits potent cytotoxicity, making it valuable in the design and development of antibody-drug conjugates (ADCs). Its application in ADC synthesis allows for targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. -
ADC Payload
(R)-Benzyl 2-cyclopropyl-2-hydroxyacetate is an ADC payload precursor, designed to facilitate the synthesis of pyrrolidines. This compound plays a crucial role in constructing targeted antibody-drug conjugates, enhancing the specificity and efficacy of therapeutic agents in cancer research. Researchers utilizing this reagent can explore advanced applications in drug development and improve therapeutic strategies. -
ADC Cytotoxin
N-Me-L-Ala-maytansinol is an ADC cytotoxin that serves as a potent cell-permeable payload for antibody-drug conjugates. It exhibits significant cytotoxic activity against target cells, making it a valuable reagent in cancer therapeutics research. This compound is instrumental in the development of targeted therapies by enhancing the selectivity and efficacy of ADCs in preclinical studies. -
ADC Cytotoxin
SC209, a 3-aminophenyl hemiasterlin derivative, targets tubulin as an ADC cytotoxin. This compound demonstrates reduced efflux potential through the P-glycoprotein 1 pump when compared to other tubulin-targeting agents, enhancing its efficacy in therapeutic applications. SC209 exhibits significant antitumor activity and is suitable for the synthesis of antibody-drug conjugates (ADCs), making it a valuable reagent in cancer research. -
ADC Cytotoxin
Duostatin 5 is an ADC cytotoxin that serves as a synthetic building block for antibody-drug conjugates (ADCs). It is derived from MMAF and allows for efficient conjugation to antibodies targeting 5T4 through a disubstituted C-Lock linker, enabling stable and straightforward synthesis. Duostatin 5 features an azide functional group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO or BCN groups. This reagent is valuable for researchers developing targeted therapies in cancer treatment. -
ADC Cytotoxin
Maytansinoid B is an ADC cytotoxin that specifically targets tubulin, acting as an antimitotic agent by inhibiting microtubule assembly. This compound can be conjugated with antibodies to form effective antibody-drug conjugates (ADCs), facilitating targeted cancer therapies. By inducing G2/M cell cycle arrest, Maytansinoid B promotes apoptosis in rapidly dividing cells, making it a valuable tool for cancer research and therapeutic applications. -
ADC Cytotoxin
N-Ac-γ-Calicheamicin-AcBut-NHS ester is an ADC cytotoxin that induces cell cycle arrest and apoptosis through the formation of DNA double-strand breaks. This compound is primarily utilized in the synthesis of antibody-drug conjugates (ADCs) and is particularly relevant in cancer research, including studies related to acute lymphoblastic leukemia (ALL) and various hematological malignancies. Its potent cytotoxic properties make it a valuable tool for advancing therapeutic strategies in oncology. -
ADC Cytotoxin
Hydrotecan is a derivative of Camptothecin, specifically designed as an antibody-drug conjugate (ADC) cytotoxin. It exhibits potent antitumor activity by inducing apoptosis in cancer cells through its action on topoisomerase I. This compound is valuable for the synthesis of ADC molecules, facilitating targeted cancer therapy research and development. -
ADC Cytotoxin
DC0-NH2 is an effector moiety targeting antibody-drug conjugates (ADCs) with enhanced stability compared to its analog DC1. This compound exhibits remarkable cytotoxicity, demonstrating approximately 1000-fold greater potency than traditional anticancer agents like Doxorubicin. The mechanism involves binding to the minor groove of DNA, leading to alkylation of adenine residues via its propabenzindole (CBI) moiety, making it a valuable candidate for cancer research and therapeutic applications. -
ADC Cytotoxin
DM3, a Maytansine analog, is a potent tubulin inhibitor that contains disulfide or thiol groups. As a key cytotoxic component of antibody-drug conjugates (ADCs), DM3 is designed to selectively target and eliminate cancer cells. Its ability to disrupt microtubule formation makes it valuable in cancer research and the development of targeted therapies. -
ADC Cytotoxin
7-MAD-MDCPT hydrochloride is a Camptothecin analog that serves as a cytotoxic payload in antibody-drug conjugates (ADCs). This compound demonstrates potent anti-cancer activity by targeting topoisomerase I, leading to DNA damage and subsequent apoptosis in cancer cells. It is primarily utilized in research focused on developing targeted cancer therapies and enhancing the efficacy of ADCs. -
ADC Cytotoxin
7-Aminomethyl-10-methyl-11-fluoro camptothecin is a potent cytotoxin targeting cancer cells through its mechanism of acting as a topoisomerase inhibitor. This compound serves as an essential intermediate for the synthesis of camptothecin-based antibody-drug conjugates (ADCs), which are designed to deliver targeted therapeutic agents to tumor cells. Its applications in cancer research support the development of innovative treatments aimed at improving the efficacy of chemotherapy while reducing systemic toxicity. -
ADC Cytotoxin
Tomaymycin DM is a derivative of tomaymycin that acts as a DNA alkylating agent, functioning primarily as a payload in antibody-drug conjugates (ADCs). This compound exhibits potent cytotoxic activity, targeting tumor cells through selective delivery mechanisms associated with ADCs. Tomaymycin DM is essential for research into targeted cancer therapies and the development of novel ADC formulations. -
ADC Cytotoxin
Exatecan Intermediate 2 hydrochloride is a cytotoxic agent targeting DNA through its mechanism as a camptothecin analog. This compound plays a critical role in the synthesis of Exatecan, an anticancer agent known for its efficacy against various malignancies, including ovarian, lung, and breast cancers. Exatecan Intermediate 2 hydrochloride is primarily utilized in research focused on cancer biology and therapeutic development. -
ADC Cytotoxin
Exatecan Intermediate 4, a key intermediate in the synthesis of Exatecan (DX-8951), functions as an ADC cytotoxin. This compound exhibits potent antitumor activity by disrupting DNA replication, leading to the inhibition of cancer cell proliferation. It is utilized in research related to various malignancies, including ovarian, lung, and breast cancers, providing insights into targeted cancer therapies and drug development. -
ADC Cytotoxin
PNU-159682 carboxylic acid is a potent cytotoxin utilized in antibody-drug conjugates (ADCs) targeting the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. This compound exhibits diverse biological activities, including modulation of cell adhesion, cell-cell signaling, and glycoprotein turnover. It plays significant roles in inflammation and immune response, making it valuable for research applications in oncology and immunology. -
ADC Cytotoxin
Maytansinoid DM4 is a thiol-containing maytansine derivative that serves as a potent cytotoxic agent. Acting as a key component in antibody-drug conjugates (ADCs), it exhibits significant biological activity by selectively targeting and destroying cancer cells. This compound is instrumental in advancing therapeutic strategies for cancer treatment research. -
ADC Payload
(1R,9S)-Dxd is an isomer of Dxd and serves as an antibody-drug conjugate (ADC) payload. Its primary mechanism involves targeted delivery of cytotoxic agents, enhancing the specificity and efficacy of ADCs in cancer therapy. This compound is utilized in the synthesis of various ADC formulations for research applications focused on improving therapeutic outcomes in oncology. -
ADC Cytotoxin
INX-SM-56 is a cytotoxin specifically designed for the synthesis of anti-VISTA antibody-drug conjugates. Targeting VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation), this compound enhances the cytotoxic efficacy of therapeutic antibodies. It is primarily utilized in cancer research to investigate immune modulation and therapeutic strategies against tumor progression. -
ADC Linker
DeBoc-Cabazitaxel serves as a versatile ADC linker, facilitating the conjugation of antibodies to cytotoxic agents for targeted therapy. This compound enhances the efficacy of antibody-drug conjugates (ADCs) by enabling selective delivery to tumor cells while minimizing off-target effects. It is particularly valuable in the development of novel cancer therapies, supporting research in targeted anti-tumor strategies. -
ADC linker
Dap-NE is an intermediate reagent specifically designed for use in the synthesis of antibody-drug conjugates (ADCs), particularly the cytotoxic agent Monomethyl auristatin E. Its role as a linker plays a critical part in ensuring the efficient delivery of therapeutic agents to targeted cells, enhancing the efficacy of the ADC. This compound is essential for researchers investigating novel ADC formulations and their applications in cancer therapeutics. -
ADC Cytotoxin
DMEA-PNU-159682 is an antibody-drug conjugate (ADC) cytotoxin that combines the metabolites of nemorubicin (MMDX) with the potent cytotoxic agent PNU-159682. This compound exhibits significant cytotoxicity, making it a valuable tool for targeted cancer therapies. Its unique mechanism of action allows for selective delivery of cytotoxic agents to tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects in research applications focused on ADC development and optimization. -
ADC Cytotoxin
DC4 is an ADC cytotoxin utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates targeted cancer therapy, enabling the selective delivery of cytotoxic agents to malignant cells while minimizing effects on healthy tissue. Its applications are particularly relevant in oncology research focused on enhancing the efficacy of cancer treatments through targeted delivery mechanisms. -
ADC Cytotoxin
DC4SMe is a phosphate proagent of the cytotoxic DNA alkylator DC4, designed for use in the synthesis of antibody-drug conjugates (ADCs). Exhibiting low IC50 values of 1.9 nM, 2.9 nM, and 1.8 nM against Ramos, Namalwa, and HL60/s cancer cell lines, respectively, DC4SMe demonstrates potent anti-cancer activity. This compound is suitable for research applications focused on targeted cancer therapies. -
ADC Cytotoxin
Diacetyl Agrochelin is an acetyl derivative of Agrochelin, targeting ADC cytotoxins for therapeutic applications. This compound demonstrates significant cytotoxic activity in various tumor cell lines, making it valuable for cancer research and development of targeted anticancer therapies. Its unique mechanism of action supports investigations into the efficacy of antibody-drug conjugates in oncological studies. -
ADC Payload
TNF-α Agonistic 2 is an agonist targeting tumor necrosis factor-alpha (TNF-α), functioning primarily as an antibody-drug conjugate (ADC) payload. This compound exhibits significant biological activity by reducing tissue thickness, as evidenced by its effects on murine models. It is applicable in research related to targeted cancer therapies and may facilitate the study of TNF-α's role in immune modulation and tumor microenvironment interactions. -
ADC Payload
Auristatin S is a potent antitumor agent designed as a payload for antibody-drug conjugates (ADCs). It exhibits significant cytotoxic activity while mitigating bystander effects and enhancing off-target toxicity profiles. Auristatin S demonstrates excellent tolerability in Karpas and KarpasBVR cell models, making it a valuable tool for targeted cancer therapies across various tumor types. Its unique properties support its application in the development of effective ADCs for cancer treatment research. -
ADC Cytotoxin
DMEA-PNU-159682 dichloroacetate acts as an antibody-drug conjugate (ADC) cytotoxin, incorporating metabolites of nemorubicin (MMDX) generated from liver microsomes along with the potent cytotoxic agent PNU-159682. This compound exhibits significant biological activity by selectively targeting cancer cells, enabling targeted delivery and enhanced therapeutic efficacy. DMEA-PNU-159682 is applicable in cancer research, specifically in studies focusing on ADC development and the evaluation of cytotoxic mechanisms. -
ADC Cytotoxin
Gly-Cyclopropane-Exatecan functions as a key component in the synthesis of antibody-drug conjugates (ADCs) targeting B7-H4. It incorporates Exatecan, a potent DNA Topoisomerase I inhibitor, into the ADC hu2F7-Exatecan, which has demonstrated significant antitumor efficacy in vivo and in vitro. This compound is relevant for cancer research, particularly in the development of targeted therapy strategies against tumor cells expressing B7-H4. -
ADC Cytotoxin
Muscotoxin A is an ADC cytotoxin that functions as a cytotoxic lipopeptide. It effectively permeabilizes mammalian cell membranes, leading to the induction of necrotic cell death. This compound is valuable in research applications involving targeted cancer therapies and the study of cellular responses to membrane disruption. -
ADC Cytotoxin
Dimethyl-SGD-1882 is a highly potent DNA alkylator, specifically designed for use as an antibody-drug conjugate (ADC) cytotoxin. It acts by forming covalent bonds with DNA, leading to the inhibition of DNA replication and subsequent induction of cytotoxicity in rapidly dividing cancer cells. This compound is valuable for research applications focused on targeted cancer therapies and the development of novel ADCs. -
ADC Cytotoxin
7-MAD-MDCPT TFA is a Camptothecin analog that serves as a cytotoxic payload for antibody-drug conjugates (ADCs). Its mechanism targets topoisomerase I, leading to the induction of apoptosis in malignant cells. This compound is relevant for research applications focused on cancer therapy, particularly in the development of targeted treatment strategies that enhance the efficacy of ADCs. -
ADC Payload
DUBA is a potent DNA alkylating agent that serves as an effective antibody-drug conjugate (ADC) payload. By covalently binding to DNA, DUBA disrupts replication and transcription processes, leading to cytotoxic effects in targeted cancer cells. Its application in synthesizing ADCs enables enhanced specificity and efficacy in delivering therapeutic agents directly to tumor sites, aiding in cancer research and treatment development. -
ADC Payload
Cryptophycin analog 1 is a potent antibody-drug conjugate (ADC) payload that targets and disrupts cancer cell proliferation. Exhibiting significant anticancer activity, this compound demonstrates cellular efficacy that is an order of magnitude greater than established ADC payloads such as MMAE and DM1. Its enhanced potency makes it a valuable tool for research in targeted cancer therapies. -
ADC Payload
NMS-P528 is a Duocarmycin derivative that functions as an antibody-drug conjugate (ADC) payload. This compound exhibits potent cytotoxic activity, providing a mechanism to selectively target and eliminate cancer cells. It can also be utilized in the synthesis of NMS-P945, facilitating advanced research in targeted therapeutic strategies. Its role in ADC development underscores its significance in cancer research applications. -
ADC Payload
N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine functions as a tubulin polymerization inhibitor and serves as an effective antibody-drug conjugate (ADC) payload. This compound disrupts microtubule dynamics, which can lead to cancer cell apoptosis. Its application in ADC development is valuable for targeted cancer therapies, enhancing the efficacy of specific antibodies against tumor cells. -
ADC Cytotoxin
Azonafide-PEABA is a cytotoxic agent specifically designed for use in antibody-drug conjugates (ADCs). This compound exhibits potent antitumor activity through its ability to interfere with cellular processes, leading to apoptosis in targeted cancer cells. Azonafide-PEABA is ideal for research applications focused on the development and optimization of ADC therapies in oncology. -
ADC Payload
7-Methylol-9-methoxy-10-F-camptothecin is a camptothecin derivative that serves as a cytotoxic payload for antibody-drug conjugates (ADCs). This compound exhibits potent antitumor activity by inhibiting topoisomerase I, leading to DNA damage and subsequent cancer cell death. Its utility in ADC synthesis makes it a valuable tool for targeted cancer therapy research and development. -
ADC Cytotoxin
NH2-methylpropanamide-Exatecan TFA is a methylpropanamide-modified form of Exatecan, an effective ADC cytotoxin targeting DNA topoisomerase I. With an IC50 of 2.2 μM, this compound plays a crucial role in cancer research by facilitating the development of antibody-drug conjugates (ADCs) for targeted therapies. The modification enhances its utility in the synthesis of ADCs, making it a valuable reagent for studies focused on therapeutic interventions in oncology. -
ADC Cytotoxin
INX-SM-6 is a potent ADC cytotoxin that selectively targets and inhibits the production of pro-inflammatory cytokines. It effectively reduces LPS-induced IL-1β production in human peripheral blood mononuclear cells (PBMCs), making it valuable for research focused on inflammation and immune response modulation. This reagent is suitable for studies aimed at developing targeted therapies for inflammatory diseases. -
ADC Cytotoxin
MMAF-methyl ester functions as an ADC (antibody-drug conjugate) cytotoxin by delivering potent therapeutic agents directly to target cells. This compound exhibits significant cytotoxic activity, disrupting cellular processes and inducing apoptosis in cancer cells. It is primarily utilized in research applications focusing on the development and optimization of targeted cancer therapies, enhancing the efficacy of antibody-based treatments. -
ADC Cytotoxin
Corixetan is a potent thorium chelator utilized in antibody-drug conjugate (ADC) applications. It effectively forms stable complexes with Th-227, providing adequate in vivo stability for targeted cytotoxic delivery. This compound is valuable for research in ADC development and radiotherapy, specifically aiming to improve therapeutic outcomes in cancer treatment. -
ADC Linker
SC209 intermediate-2 is an ADC linker designed for use in antibody-drug conjugate (ADC) synthesis. This compound serves as an essential intermediate for the cytotoxin SC209, enabling targeted delivery of therapeutic agents to cancer cells. SC209 intermediate-2 plays a crucial role in enhancing the efficacy of ADCs in research applications focused on cancer treatment and drug development. -
ADC Cytotoxin
10NH2-11F-Camptothecin TFA is a derivative of Camptothecin designed for use as an antibody-drug conjugate (ADC) cytotoxin. This compound exhibits potent anticancer activity, making it suitable for the development of targeted cancer therapeutics. Its application in ADC formulation allows for enhanced specificity and efficacy in targeting tumor cells. -
ADC Cytotoxin
Dov-Val-Dil-OH is an antibody-drug conjugate (ADC) cytotoxin designed for targeted cancer therapy. It exhibits potent cytotoxic activity by selectively killing tumor cells upon internalization. This compound is primarily utilized in the development and evaluation of ADCs, allowing researchers to study its efficacy in various cancer models. -
ADC Cytotoxin
Exatecan-2-(aminomethoxy)acetamide-Gly-Fmoc is an antibody-drug conjugate (ADC) cytotoxin designed for targeted cancer therapy. This compound exerts its cytotoxic effects primarily through the inhibition of topoisomerase I, leading to DNA damage and subsequent cell death in malignant cells. It is utilized in research for the development of innovative ADCs, optimizing delivery mechanisms for enhanced tumor selectivity and therapeutic efficacy. -
Drug-Linker Conjugate For ADC
LP-6 TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This compound integrates an Eg5 inhibitor with a linker, facilitating targeted drug delivery and enhancing therapeutic efficacy. It is suitable for research applications focused on the development and optimization of ADCs in cancer therapy. -
ADC Linker
BCN-linker-DXd 2 is a specialized ADC (antibody-drug conjugate) linker designed for targeted delivery of cytotoxic agents to cancer cells. This compound facilitates the conjugation of drugs to antibodies, enhancing specificity and reducing off-target effects in cancer therapy. It is applicable in research focused on ADC development and optimization for improved therapeutic efficacy against various types of tumors. -
Drug-Linker Conjugate for ADC
MC-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADCs). It employs the potent tubulin inhibitor MMAF, which is covalently linked via the cathepsin-cleavable peptide MC-Val-Cit-PAB. This compound exhibits significant antitumor activity, making it valuable for research applications in cancer therapy and development of targeted drug delivery systems.
